Daiwa Securities Group
KPTI icon

Daiwa Securities Group’s Karyopharm Therapeutics KPTI Stock Holding History

Daiwa Securities Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18
Closed -$1K – 1188
2019
Q2 		$1K Buy
+18
New +$1.45K ﹤0.01% 1179

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Daiwa Securities Group's KPTI Position: Q4 2023 in Review

Daiwa Securities Group sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 9 shares.

Daiwa Securities Group first reported a position in KPTI in Q1 2018 and held it in 23 quarters. The position peaked at $7K in Q2 2020. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Daiwa Securities Group reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 9 Karyopharm Therapeutics shares in Q4 2023.
  • Daiwa Securities Group first reported a position in Karyopharm Therapeutics in Q1 2018 and held it in 23 quarters.
  • Daiwa Securities Group's Karyopharm Therapeutics position peaked at $7K in Q2 2020.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.